|
||
Hifenac Dosage |
||
Generic name: Hifenac 18mg
Dosage form: capsule
The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.
Carefully consider the potential benefits and risks of Hifenac and other treatment options before deciding to use Hifenac. Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals.
The effectiveness of Hifenac when taken with food has not been studied in clinical studies. Taking Hifenac with food may cause a reduction in effectiveness compared to taking Hifenac on an empty stomach.
Acute Pain
For management of mild to moderate acute pain, the dosage is 18 mg or 35 mg orally three times daily.
Osteoarthritis Pain
For management of osteoarthritis pain, the dosage is 35 mg orally three times daily.
Patients with hepatic disease may require reduced doses of Hifenac compared to patients with normal hepatic function. As with other Hifenac products, start treatment at the lowest dose. If efficacy is not achieved with the lowest dose, discontinue use.
Hifenac capsules are not interchangeable with other formulations of oral Hifenac even if the milligram strength is the same. Hifenac capsules contain Hifenac free acid whereas other Hifenac products contain a salt of Hifenac, i.e., Hifenac potassium or sodium. A 35 mg dose of Hifenac is approximately equal to 37.6 mg of sodium Hifenac or 39.5 mg of potassium Hifenac. Therefore, do not substitute similar dosing strengths of other Hifenac products without taking this into consideration.
Ask your doctor before using Hifenac if you take an antidepressant such as citalopram, escitalopram, fluoxetine (Prozac), fluvoxamine, paroxetine, sertraline (Zoloft), trazodone, or vilazodone. Taking any of these medicines with an NSAID may cause you to bruise or bleed easily.
Tell your doctor about all your current medicines and any you start or stop using, especially:
cyclosporine;
lithium;
methotrexate;
rifampin;
antifungal medicine;
a blood thinner (warfarin, Coumadin, Jantoven);
heart or blood pressure medication, including a diuretic or "water pill";
other forms of Hifenac (Flector, Pennsaid, Solaraze, Hifenac Gel);
other NSAIDs - aspirin, ibuprofen (Advil, Motrin), naproxen (Aleve), celecoxib (Celebrex), indomethacin, meloxicam, and others; or
steroid medicine (prednisone and others).
This list is not complete. Other drugs may interact with Hifenac, including prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed in this medication guide.
Aspirin: Concomitant administration of Hifenac and aspirin is not recommended because Hifenac is displaced from its binding sites during the concomitant administration of aspirin, resulting in lower plasma concentrations, peak plasma levels and AUC values.
Anticoagulants: While studies have not shown Hifenac to interact with anticoagulants of the warfarin type, caution should be exercised, nonetheless, since interactions have been seen with other NSAIDs. Because prostaglandins play an important role in hemostasis and NSAIDs affect platelet function as well, concurrent therapy with all NSAIDs, including Hifenac and warfarin, requires close monitoring of patients to be certain that no change in their anticoagulant dosage is required.
Digoxin, Methotrexate, Cyclosporine: Hifenac, like other NSAIDs, may affect renal prostaglandins and increase the toxicity of certain drugs. Ingestion of Hifenac may increase serum concentrations of digoxin and methotrexate and increase cyclosporine's nephrotoxicity. Patients who begin taking Hifenac or who increase their Hifenac dose or any other NSAID while taking digoxin, methotrexate or cyclosporine may develop toxicity characteristics for these drugs. They should be observed closely, particularly if renal function is impaired. In the case of digoxin, serum levels should be monitored.
Lithium: Hifenac decreases lithium renal clearance and increases lithium plasma levels. In patients taking Hifenac and lithium concomitantly, lithium toxicity may develop.
Diuretics: Hifenac and other NSAIDs can inhibit the activity of diuretics. Concomitant treatment with potassium-sparing diuretics may be associated with increased serum potassium levels.
Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of azathioprine, gold, chloroquine, D-penicillamine, prednisolone, doxycycline or digitoxin did not significantly affect the peak levels and AUC values of Hifenac. Phenobarbital toxicity has been reported to have occurred in a patient on chronic phenobarbital treatment following the initiation of Hifenac therapy.
Users | % | ||
---|---|---|---|
51-100mg | 1 | 100.0% |
need some description about drug interactions... |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|